G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August 2020

Rhea-AI Summary

G1 Therapeutics, a clinical-stage oncology company, announced an upcoming presentation by CEO Mark Velleca at two investor conferences in August 2020. The presentations are scheduled for:

• BTIG Virtual Biotechnology Conference on August 10, 2020, at 11:30 a.m. ET
• Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 10:55 a.m. ET

Interested parties can access live and archived webcasts on the company’s Events & Presentations page. G1 Therapeutics focuses on innovative cancer therapies, including its FDA-designated Breakthrough Therapy, Trilaciclib.

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present company updates at two investor conferences in August 2020:

• BTIG Virtual Biotechnology Conference 2020 on Monday, August 10, 2020 at 11:30 a.m. ET
• 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:55 a.m. ET

To access live and archived webcasts of the presentations, please visit the Events & Presentations page of the G1 website.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class FDA-designated Breakthrough Therapy designed to improve outcomes for patients being treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
G1 Therapeutics, Inc.
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com

FAQ

What events will G1 Therapeutics attend in August 2020?

G1 Therapeutics will present at the BTIG Virtual Biotechnology Conference on August 10, 2020, and the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020.

Who is presenting for G1 Therapeutics at the conferences?

Mark Velleca, M.D., Ph.D., the CEO of G1 Therapeutics, will present company updates.

How can I access the presentations from G1 Therapeutics?

Live and archived webcasts of the presentations can be accessed on the Events & Presentations page of the G1 Therapeutics website.

What is Trilaciclib, developed by G1 Therapeutics?

Trilaciclib is a first-in-class therapy designated as a Breakthrough Therapy by the FDA, aimed at improving outcomes for chemotherapy patients.

What is the focus of G1 Therapeutics as a company?

G1 Therapeutics focuses on the discovery, development, and delivery of innovative therapies to improve the lives of cancer patients.